5.39
前日終値:
$5.34
開ける:
$5.49
24時間の取引高:
48,593
Relative Volume:
0.99
時価総額:
$203.96M
収益:
$15.33M
当期純損益:
$-40.19M
株価収益率:
-3.0761
EPS:
-1.7522
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+7.80%
1か月 パフォーマンス:
+4.86%
6か月 パフォーマンス:
+13.95%
1年 パフォーマンス:
-22.11%
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
名前
Trisalus Life Sciences Inc
セクター
電話
415 336 8917
住所
6272 WEST 91ST AVENUE, WESTMINSTER
TLSI を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TLSI
Trisalus Life Sciences Inc
|
5.39 | 207.36M | 15.33M | -40.19M | 0 | -1.7522 |
![]()
ABT
Abbott Laboratories
|
133.58 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
102.09 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
383.89 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.44 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
77.52 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-13 | 開始されました | Lake Street | Buy |
2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
2024-11-11 | 開始されました | ROTH MKM | Buy |
2024-10-25 | 開始されました | Northland Capital | Outperform |
2024-09-16 | 開始されました | Oppenheimer | Outperform |
2024-05-30 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Trisalus Life Sciences Inc (TLSI) 最新ニュース
TriSalus Launches TriNav FLX To Enhance Drug Delivery In Complex Peripheral Vessels - Nasdaq
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Bluefield Daily Telegraph
TriSalus Unveils Next-Gen Cancer Treatment Device: New TriNav FLX Shows 28% Better Navigation - Stock Titan
Northern Trust Corp Has $161,000 Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Cantor Fitzgerald maintains TriSalus stock rating after CFO change By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains TriSalus stock rating after CFO change - Investing.com
TriSalus Life Sciences names new CFO - BizWest
TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Comm - GuruFocus
TriSalus Life Sciences (TLSI) Names New Chief Financial Officer - GuruFocus
TriSalus Life Sciences (TLSI) Plans to Offer 5.5M Shares of Common Stock | TLSI Stock News - GuruFocus
TriSalus Life Sciences Appoints David Patience as CFO - marketscreener.com
TriSalus Life Sciences Appoints David Patience To Succeed James Young As CFO - Nasdaq
TriSalus Names David Patience Finance Chief as James Young Departs - MarketWatch
TriSalus Life Sciences appoints new CFO amid transition - Investing.com
TriSalus Life Sciences, Inc. Announces Chief Financial Officer Changes - marketscreener.com
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 3.9% – Should You Buy? - Defense World
Roth Capital Issues Negative Estimate for TLSI Earnings - Defense World
TLSI FY2025 EPS Estimate Reduced by Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains $9 target on TriSalus stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains $9 target on TriSalus stock - Investing.com Australia
TriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable market - MSN
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript - MSN
Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) PT at $10.93 - Defense World
Trisalus Life Sciences Q1 2025 Earnings Call Highlights - TipRanks
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: TriSalus Life Sciences projects 50% revenue growth in Q1 2025 - Investing.com Nigeria
TriSalus Life Sciences Reports Strong Q1 2025 Growth - TipRanks
Transcript : TriSalus Life Sciences, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
TriSalus (TLSI) Exceeds Revenue Expectations in Q1 | TLSI Stock News - GuruFocus
Trisalus Life Sciences Q1 Pretax Profit USD -10.37 Million - marketscreener.com
TriSalus Life Sciences, Inc. Updates Earnings Guidance for the Year 2025 - marketscreener.com
TriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on Wednesday - Defense World
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call - Business Wire
13,400 Shares in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Acquired by Renaissance Technologies LLC - Defense World
Geode Capital Management LLC Purchases 3,710 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Northland maintains TriSalus stock with $12.50 target - Investing.com Australia
Northland maintains TriSalus stock with $12.50 target By Investing.com - Investing.com India
TLSI Reports Strong Revenue Growth in First Quarter of 2025 | TL - GuruFocus
TriSalus Life Sciences (TLSI) Secures $22M Investment and Plans Capital Restructuring | TLSI Stock News - GuruFocus
TriSalus Life Sciences secures $22 million in funding By Investing.com - Investing.com India
TriSalus Life Sciences secures $22 million in funding - Investing.com
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results - Business Wire
TriSalus Life Sciences files to offer up to 3.34M shares - MSN
TriSalus Life Sciences announces board member resignation By Investing.com - Investing.com Canada
TriSalus Life Sciences announces board member resignation - Investing.com Australia
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $11.56 Average Price Target from Analysts - Defense World
TriSalus Life Sciences, Inc. SEC 10-K Report - TradingView
VAREX IMAGING (VREX) Moves 16.5% Higher: Will This Strength Last? - Yahoo Finance
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? - Nasdaq
Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com
TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Monday - Defense World
Trisalus Life Sciences Inc (TLSI) 財務データ
収益
当期純利益
現金流量
EPS
Trisalus Life Sciences Inc (TLSI) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Devlin Jodi | Chief of Clinical Operations |
May 19 '25 |
Sale |
5.18 |
4,764 |
24,678 |
52,764 |
Marshak Richard | Chief Commercial Officer |
May 19 '25 |
Sale |
5.18 |
6,597 |
34,172 |
69,101 |
Stevens Jennifer | Chief Regulatory Officer |
May 19 '25 |
Sale |
5.18 |
8,704 |
45,087 |
77,640 |
Young James Emmett | Chief Financial Officer |
Feb 05 '25 |
Buy |
5.65 |
6,000 |
33,900 |
30,000 |
Szela Mary T | CEO AND PRESIDENT |
Jan 30 '25 |
Buy |
5.28 |
5,010 |
26,453 |
444,259 |
Szela Mary T | CEO AND PRESIDENT |
Jan 29 '25 |
Buy |
5.03 |
5,030 |
25,301 |
439,249 |
Szela Mary T | CEO AND PRESIDENT |
Jan 27 '25 |
Buy |
5.42 |
4,826 |
26,157 |
429,503 |
Szela Mary T | CEO AND PRESIDENT |
Jan 28 '25 |
Buy |
5.12 |
4,716 |
24,146 |
434,219 |
Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 27 '25 |
Buy |
5.31 |
15,000 |
79,650 |
182,732 |
Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 28 '25 |
Buy |
5.17 |
15,000 |
77,550 |
197,732 |
大文字化:
|
ボリューム (24 時間):